Evofem Biosciences, Inc. (EVFM)

0.4100 +0.0149 (+3.77%) At close: 04:00PM EST

Evofem Biosciences, Inc.

12400 High Bluff Drive
Suite 600
San Diego, CA 92130
United States
858 550 1900
https://www.evofem.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 147

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Saundra Pelletier	Pres, CEO & Director	1.84M	N/A	1970
Mr. Justin J. File	Chief Financial Officer	1.01M	N/A	1970
Mr. Russell Barrans	Chief Commercial Officer	762.98k	N/A	1960
Ms. Amy Raskopf	VP of Investor Relations	N/A	N/A	N/A
Mr. Alexander A. Fitzpatrick Esq.	Exec. VP, Gen. Counsel & Sec.	N/A	N/A	1967
Kathy Gallo-Doyle	VP of Sales	N/A	N/A	N/A
Dr. Kelly Culwell M.D.	Chief Medical Officer	N/A	N/A	1974

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Corporate Governance

Evofem Biosciences, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.